This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gallagher, J. C. Articles by McClung, M. Search for Related Content PubMed PubMed Citation Articles by Gallagher, J. C. Articles by McClung, M.

Prevention of Bone Loss with Tibolone in Postmenopausal Women: Results of Two Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Studies

Creighton University Medical Center (J.C.G.), Omaha, Nebraska 68131; Jerry L. Pettis VA Medical Center (D.J.B.), Loma Linda, California 92357; Albert Einstein College of Medicine (R.F.), Bronx, New York 10461; and Oregon Osteoporosis Center (M.M.), Portland, Oregon 97213

Address all correspondence and requests for reprints to: J. Christopher Gallagher, M.D., Creighton University Medical Center, St. Joseph’s Hospital, 601 North 30th Street, Suite 6712, Omaha, Nebraska 68131. E-mail: jcg{at}creighton.edu

Abstract

Tibolone, a novel compound with tissue-specific effects, has been found to have antiresorptive properties in bone. To confirm the efficacy of tibolone and determine its minimum effective dose for prevention of bone loss in early postmenopausal women, two randomized, double-blind, placebocontrolled, dose-finding studies were performed.

Seven hundred seventy healthy women postmenopausal within 1–4 yr, with normal bone density for their age, were treated for 2 yr with 0.3, 0.625, 1.25, or 2.5 mg tibolone daily or placebo. All subjects took supplemental calcium carbonate (500 mg daily). Bone mineral density (BMD) of the lumbar spine and right proximal femur was measured by dual-energy x-ray absorptiometry for up to 2 yr.

At each dose level, except the lowest (0.3 mg), tibolone produced a progressive increase in lumbar spine and total hip BMD over the 2-yr treatment period; at 0.3 mg, total hip density was maintained. However, only the doses 1.25 mg and 2.5 mg produced a progressive increase in femoral neck BMD. The differences in mean percent change from baseline in spine and total hip density were significant (P < 0.05) for all tibolone dose groups compared with placebo at all time points. Tibolone was well tolerated, with a similar overall incidence of adverse events compared with placebo. Tibolone 1.25 mg per day is recommended because it shows a positive and statistically significant change in BMD of spine and femoral neck.

This article has been cited by other articles:

				H. D. Nelson, R. Fu, J. C. Griffin, P. Nygren, M.E. B. Smith, and L. Humphrey Systematic Review: Comparative Effectiveness of Medications to Reduce Risk for Primary Breast Cancer Ann Intern Med, September 14, 2009; (2009) 0000605-200911170-00147v1. [Abstract] [Full Text]

				R. T. Chlebowski, R. Prentice, M. Serati, S. Uccella, P. Bolis, S. R. Cummings, and V. Stathopolous Tibolone in Older Postmenopausal Women N. Engl. J. Med., November 13, 2008; 359(20): 2172 - 2173. [Full Text] [PDF]

				S. R. Cummings, B. Ettinger, P. D. Delmas, P. Kenemans, V. Stathopoulos, P. Verweij, M. Mol-Arts, L. Kloosterboer, L. Mosca, C. Christiansen, et al. The Effects of Tibolone in Older Postmenopausal Women N. Engl. J. Med., August 14, 2008; 359(7): 697 - 708. [Abstract] [Full Text] [PDF]

				D. F. Archer, S. Hendrix, J. C. Gallagher, J. Rymer, S. Skouby, A. Ferenczy, W. den Hollander, V. Stathopoulos, F. A. Helmond, and for the Tibolone Histology of the Endometrium and Endometrial Effects of Tibolone J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 911 - 918. [Abstract] [Full Text] [PDF]

				J. M Swegle and M. W Kelly Tibolone: A Unique Version of Hormone Replacement Therapy Ann. Pharmacother., May 1, 2004; 38(5): 874 - 881. [Abstract] [Full Text] [PDF]

				M. Doren, J.-A. Nilsson, and O. Johnell Effects of specific post-menopausal hormone therapies on bone mineral density in post-menopausal women: a meta-analysis Hum. Reprod., August 1, 2003; 18(8): 1737 - 1746. [Abstract] [Full Text] [PDF]

				L. J. Blok, P. E. De Ruiter, E. C. M. Kuhne, E. E. Hanekamp, J. A. Grootegoed, E. Smid-Koopman, S. C. J. P. Gielen, M. E. De Gooyer, H. J. Kloosterboer, and C. W. Burger Progestagenic Effects of Tibolone on Human Endometrial Cancer Cells J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 2327 - 2334. [Abstract] [Full Text] [PDF]

				J. E. Morley and H. M. Perry III Androgens and Women at the Menopause and Beyond J. Gerontol. A Biol. Sci. Med. Sci., May 1, 2003; 58(5): M409 - 416. [Full Text] [PDF]

				K. Modelska and S. Cummings Tibolone for Postmenopausal Women: Systematic Review of Randomized Trials J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 16 - 23. [Abstract] [Full Text] [PDF]